• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application
o Anthrax – Market size and forecast 2019-2024
o Smallpox – Market size and forecast 2019-2024
o Botulism – Market size and forecast 2019-2024
o Others – Market size and forecast 2019-2024
o Market opportunity by Application
• Customer Landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
o Competitive scenario
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Alexeter Technologies LLC
o Alnylam Pharmaceuticals Inc.
o Altimmune Inc.
o ANP Technologies Inc.
o Bavarian Nordic AS
o Cleveland BioLabs Inc.
o Elusys Therapeutics Inc.
o Emergent BioSolutions Inc.
o General Dynamics Corp.
o GlaxoSmithKline Plc
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2019 – 2024 ($ million)
• 13: Global market: Year-over-year growth 2019 – 2024 (%)
• 14: Five forces analysis 2019 & 2024
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2019
• 21: Application – Market share 2019-2024 (%)
• 22: Comparison by Application
• 23: Anthrax – Market size and forecast 2019-2024 ($ million)
• 24: Anthrax – Year-over-year growth 2019-2024 (%)
• 25: Smallpox – Market size and forecast 2019-2024 ($ million)
• 26: Smallpox – Year-over-year growth 2019-2024 (%)
• 27: Botulism – Market size and forecast 2019-2024 ($ million)
• 28: Botulism – Year-over-year growth 2019-2024 (%)
• 29: Others – Market size and forecast 2019-2024 ($ million)
• 30: Others – Year-over-year growth 2019-2024 (%)
• 31: Market opportunity by Application
• 32: Customer landscape
• 33: Market share by geography 2019-2024 (%)
• 34: Geographic comparison
• 35: North America – Market size and forecast 2019-2024 ($ million)
• 36: North America – Year-over-year growth 2019-2024 (%)
• 37: Europe – Market size and forecast 2019-2024 ($ million)
• 38: Europe – Year-over-year growth 2019-2024 (%)
• 39: Asia – Market size and forecast 2019-2024 ($ million)
• 40: Asia – Year-over-year growth 2019-2024 (%)
• 41: ROW – Market size and forecast 2019-2024 ($ million)
• 42: ROW – Year-over-year growth 2019-2024 (%)
• 43: Key leading countries
• 44: Market opportunity by geography ($ million)
• 45: Impact of drivers and challenges
• 46: Vendor landscape
• 47: Landscape disruption
• 48: Industry risks
• 49: Vendors covered
• 50: Market positioning of vendors
• 51: Alexeter Technologies LLC – Overview
• 52: Alexeter Technologies LLC – Product and service
• 53: Alexeter Technologies LLC – Key offerings
• 54: Alexeter Technologies LLC – Key customers
• 55: Alexeter Technologies LLC – Segment focus
• 56: Alnylam Pharmaceuticals Inc. – Overview
• 57: Alnylam Pharmaceuticals Inc. – Product and service
• 58: Alnylam Pharmaceuticals Inc. – Key offerings
• 59: Alnylam Pharmaceuticals Inc. – Key customers
• 60: Alnylam Pharmaceuticals Inc. – Segment focus
• 61: Altimmune Inc. – Overview
• 62: Altimmune Inc. – Business segments
• 63: Altimmune Inc. – Key offerings
• 64: Altimmune Inc. – Key customers
• 65: Altimmune Inc. – Segment focus
• 66: ANP Technologies Inc. – Overview
• 67: ANP Technologies Inc. – Product and service
• 68: ANP Technologies Inc. – Key offerings
• 69: ANP Technologies Inc. – Key customers
• 70: ANP Technologies Inc. – Segment focus
• 71: Bavarian Nordic AS – Overview
• 72: Bavarian Nordic AS – Business segments
• 73: Bavarian Nordic AS – Key offerings
• 74: Bavarian Nordic AS – Key customers
• 75: Bavarian Nordic AS – Segment focus
• 76: Cleveland BioLabs Inc. – Overview
• 77: Cleveland BioLabs Inc. – Product and service
• 78: Cleveland BioLabs Inc. – Key offerings
• 79: Cleveland BioLabs Inc. – Key customers
• 80: Cleveland BioLabs Inc. – Segment focus
• 81: Elusys Therapeutics Inc. – Overview
• 82: Elusys Therapeutics Inc. – Product and service
• 83: Elusys Therapeutics Inc. – Key offerings
• 84: Elusys Therapeutics Inc. – Key customers
• 85: Elusys Therapeutics Inc. – Segment focus
• 86: Emergent BioSolutions Inc. – Overview
• 87: Emergent BioSolutions Inc. – Business segments
• 88: Emergent BioSolutions Inc. – Key offerings
• 89: Emergent BioSolutions Inc. – Key customers
• 90: Emergent BioSolutions Inc. – Segment focus
• 91: General Dynamics Corp. – Overview
• 92: General Dynamics Corp. – Business segments
• 93: General Dynamics Corp. – Key offerings
• 94: General Dynamics Corp. – Key customers
• 95: General Dynamics Corp. – Segment focus
• 96: GlaxoSmithKline Plc – Overview
• 97: GlaxoSmithKline Plc – Business segments
• 98: GlaxoSmithKline Plc – Key offerings
• 99: GlaxoSmithKline Plc – Key customers
• 100: GlaxoSmithKline Plc – Segment focus
• 101: Currency conversion rates for US$
• 102: Research Methodology
• 103: Validation techniques employed for market sizing
• 104: Information sources
• 105: List of abbreviations
【掲載企業】
Alexeter Technologies LLC, Alnylam Pharmaceuticals Inc., Altimmune Inc., ANP Technologies Inc., Bavarian Nordic AS, Cleveland BioLabs Inc., Elusys Therapeutics Inc., Emergent BioSolutions Inc., General Dynamics Corp., GlaxoSmithKline Plc